Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
Stock Information for Cardiff Oncology Inc.
Loading
Please wait while we load your information from QuoteMedia.